MorphoSys (ETR:MOR) Hits New 1-Year High at $114.70
MorphoSys AG (ETR:MOR)’s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as €114.70 ($133.37) and last traded at €114.20 ($132.79), with a volume of 77124 shares trading hands. The stock had previously closed at €111.50 ($129.65).
Several equities research analysts recently commented on the company. Berenberg Bank set a €150.00 ($174.42) target price on MorphoSys and gave the company a “buy” rating in a report on Monday, August 5th. JPMorgan Chase & Co. set a €120.00 ($139.53) target price on MorphoSys and gave the company a “buy” rating in a report on Wednesday, August 7th. Royal Bank of Canada set a €130.00 ($151.16) target price on MorphoSys and gave the company a “buy” rating in a report on Friday, August 9th. HSBC set a €81.00 ($94.19) target price on MorphoSys and gave the company a “sell” rating in a report on Friday, August 16th. Finally, Independent Research set a €116.00 ($134.88) target price on MorphoSys and gave the company a “neutral” rating in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. MorphoSys currently has an average rating of “Hold” and a consensus target price of €118.56 ($137.86).
The company has a debt-to-equity ratio of 8.61, a quick ratio of 7.40 and a current ratio of 7.62. The firm has a fifty day simple moving average of €101.82 and a 200-day simple moving average of €92.23. The company has a market capitalization of $3.60 billion and a PE ratio of -86.22.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Read More: Put Option
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.